Human growth hormone (somatropin) for the treatment of growth failure in children

  • Technology appraisal guidance
  • TA188
  • Published: 
Download guidance (PDF)

8 Sources of evidence considered by the Committee

The assessment report for this appraisal was prepared by the Southampton Health Technology Assessments Centre:

  • Takeda A, Cooper K, Bird A, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation, August 2009

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Manufacturers, or sponsors, professional or specialist and patient or carer groups, and other consultees, were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Eli Lilly

  • Ferring Pharmaceuticals

  • Ipsen

  • Merck Serono

  • Novo Nordisk

  • Pfizer Ltd

  • Sandoz Ltd

Professional or specialist and patient or carer groups:

  • Child Growth Foundation

  • British Society For Paediatric Endocrinology and Diabetes

  • Pituitary Foundation

  • Royal College of Nursing

  • Royal College of Paediatrics and Child Health

  • Royal College of Pathologists

  • Royal College of Physicians

  • Society for Endocrinology

  • Turner Syndrome Support Society

Other consultees:

  • Department of Health

  • Welsh Assembly Government

Commentator organisations (without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Medicines and Healthcare products Regulatory Agency (MHRA)

  • NHS Quality Improvement Scotland

The following individuals were selected from clinical specialist and patient expert nominations from the non‑manufacturer or sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on human growth hormone for the treatment of growth failure in children by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Gary Butler, Professor of Paediatrics and Growth, nominated by the British Society for Paediatric Endocrinology and Diabetes – clinical specialist

  • Professor Peter Hindmarsh, Professor of Paediatric Endocrinology, University College London, nominated by the Royal College of Physicians – clinical specialist

  • Professor Christopher Kelnar, Professor of Paediatric Endocrinology, University of Edinburgh, nominated by NHS Quality Improvement Scotland – clinical specialist

  • Mr Tam Fry, nominated by the Child Growth Foundation – patient expert

  • Mrs Arlene Smyth, nominated by the Turner Syndrome Support Society – patient expert

ISBN: 978-1-4731-5626-5